Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut over the last week. The news is piling up now the summer is coming to an end so expect more here next week….
- The British Heart Foundation launched a new €33M global research award to encourage innovation in cardiovascular disease research
- Evotec will search for new drugs for rare diseases using its induced pluripotent stem cell platform and drug discovery know-how in collaboration with Centogene’s genetic testing and biomarker knowledge
- Evotec also extended its 2015 alliance with the US Huntington’s research foundation CHDI until 2023 to continue to research treatments for the devasting genetic condition
- Cambridge-based Metrion Biosciences will receive €706,250 from the Innovate UK Biomedical Catalyst Primer Award scheme to help develop new psoriasis drugs
- Austrian biotech PhagoMed Biopharma raised €4M in grants and investments to develop new antimicrobials using bacteria-eating viruses called phages
- Liquid biopsy company Angle’s lead product Parsortix can detect circulating tumor cells in the blood of patients with glioblastoma, according to research from the University of Basel, showing that such cells can cross the blood-brain barrier
- Swiss biotech Urovant Sciences has licensed an investigational gene therapy for overactive bladder from US company Ion Channel Innovations and will apply to start a Phase II trial in the US next year
- Swiss Cancer diagnostics firm Lunaphore, which develops technology that can diagnose cancer from tissue samples, closed its €10M series B financing round
- The Fraunhofer Institute for Cell Therapy and Immunology in Leipzig has signed another collaboration with Novartis — and extension of their 2015 agreement — to produce newly approved Kymriah, plus other investigational CAR-T cell therapies, for cancer patients in Europe
- AstraZeneca and MedImmune announced their Phase III trial for their lupus candidate drug anifrolumab has failed
- A 4-year, €9.5M scheme has been funded by the Academy of Finland to encourage innovation in the country and develop materials from renewable sources such as forest biomass
Images: E. Resko
Let's Continue The Conversation
Feel free to send us comments about this article to email@example.com and/or comment on that article on social media.